...
首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy.
【24h】

Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy.

机译:MammoSite乳房近距离放射治疗器在通过保乳疗法治疗的早期乳腺癌女性中的初步临床经验。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: We present the results of the initial clinical testing of the MammoSite balloon breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. METHODS AND MATERIALS: Seventy patients were enrolled in a multicenter prospective trial testing the applicator for safety and performance. Fifty-four patients were implanted, and 43 patients were ultimately eligible for and received brachytherapy as the sole radiation modality after lumpectomy. Patients were staged T1N0M0 with negative pathologic margins and age >45 years. A dose of 34 Gy was delivered in 10 fractions over 5 days prescribed to 1 cm from the applicator surface using 192Ir high-dose-rate brachytherapy. A minimum skin-to-balloon surface distance of 5 mm was required for treatment. Device performance, complications, and cosmesis were assessed. RESULTS: Computed tomography imaging post-balloon inflation showed 8, 14, and 21 patients with 5-6 mm, 7-9 mm, and >10 mm of skin spacing, respectively. Two patients were explanted because of inadequate skin spacing and 7 because of suboptimal conformance of the surgical cavity to the applicator balloon. One patient was explanted because of positive nodal status and another because of age. The most common side effects related to device placement included mild erythema, drainage, pain, and echymosis. No severe side effects related to implantation, brachytherapy, or explantation occurred. Side effects related to radiation therapy were generally mild with erythema, pain, and dry desquamation being the most common. At 1 month, 88% of patients were evaluated as having good-to-excellent cosmetic results. CONCLUSIONS: The MammoSite balloon breast brachytherapy applicator performed well clinically. All eligible patients completed treatment. Side effects were mild to moderate and self-limiting. Skin-balloon surface distance and balloon-cavity conformance were the main factors limiting the initial use of the device.
机译:目的:我们介绍了MammoSite球囊乳房近距离放射治疗器在保留乳腺癌治疗的早期乳腺癌妇女中的初步临床测试结果。方法和材料:70名患者参加了一项多中心前瞻性试验,测试了涂药器的安全性和性能。植入了54例患者,最终有43例患者接受了肿块切除术后唯一的放射疗法并接受了近距离放射治疗。患者分期为T1N0M0,病理切缘阴性,年龄> 45岁。使用192Ir高剂量率近距离放射治疗,在距施药器表面1 cm的位置规定的5天内,将10天的34 Gy剂量分批递送。治疗需要的皮肤到气球的最小表面距离为5 mm。评估设备性能,并发症和美容效果。结果:气球X线计算机断层扫描成像显示8、14和21例患者的皮肤间距分别为5-6 mm,7-9 mm和> 10 mm。由于皮肤间隙不足而将2例患者移出,由于手术腔与涂药器球囊的最佳贴合而将7例移出。一名患者因淋巴结转移阳性而被移植,另一名患者因年龄而被移植。与设备放置有关的最常见的副作用包括轻度红斑,引流,疼痛和手足病。没有发生与植入,近距离治疗或植入相关的严重副作用。与放射疗法有关的副作用通常较轻,以红斑,疼痛和干燥脱皮为最常见。在1个月时,有88%的患者被评估为具有良好至出色的美容效果。结论:MammoSite气球乳腺近距离放射治疗器在临床上表现良好。所有符合条件的患者均已完成治疗。副作用为轻度至中度和自我限制。皮肤气球表面距离和球囊腔顺应性是限制该设备初始使用的主要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号